Trials / Completed
CompletedNCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
Conditions
- Non-Hodgkins Lymphoma
- B-cell Lymphoma
- Waldenstrom's Macroglobulinemia
- Marginal Zone Lymphoma
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Primary Central Nervous System Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ublituximab | Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20) |
Timeline
- Start date
- 2012-07-19
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2012-07-24
- Last updated
- 2022-11-21
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01647971. Inclusion in this directory is not an endorsement.